165 related articles for article (PubMed ID: 35675421)
1. Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.
Patel R; Ford CA; Rodgers L; Rushworth LK; Fleming J; Mui E; Zhang T; Watson D; Lynch V; Mackay G; Sumpton D; Sansom OJ; Vande Voorde J; Leung HY
Cancer Res; 2022 Jul; 82(14):2565-2575. PubMed ID: 35675421
[TBL] [Abstract][Full Text] [Related]
2. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
Kurosawa Y; Degrauw TJ; Lindquist DM; Blanco VM; Pyne-Geithman GJ; Daikoku T; Chambers JB; Benoit SC; Clark JF
J Clin Invest; 2012 Aug; 122(8):2837-46. PubMed ID: 22751104
[TBL] [Abstract][Full Text] [Related]
3. Liposomal Delivery of Cyclocreatine Impairs Cancer Cell Bioenergetics Mediating Apoptosis.
Ganguly S; Elbayoumi T
Methods Mol Biol; 2021; 2275():173-186. PubMed ID: 34118038
[TBL] [Abstract][Full Text] [Related]
4. Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency.
Do MT; Cavagnaro J; Butt M; Terse PS; McKew JC
Regul Toxicol Pharmacol; 2021 Jul; 123():104939. PubMed ID: 33961952
[TBL] [Abstract][Full Text] [Related]
5. Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts.
Gorshkov K; Wang AQ; Sun W; Fisher E; Frigeni M; Singleton M; Thorne N; Class B; Huang W; Longo N; Do MT; Ottinger EA; Xu X; Zheng W
Pharmacol Res Perspect; 2019 Dec; 7(6):e00525. PubMed ID: 31859463
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
7. Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts.
Uemura T; Ito S; Masuda T; Shimbo H; Goto T; Osaka H; Wada T; Couraud PO; Ohtsuki S
Pharm Res; 2020 Mar; 37(3):61. PubMed ID: 32124083
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Matthews RT; Yang L; Jenkins BG; Ferrante RJ; Rosen BR; Kaddurah-Daouk R; Beal MF
J Neurosci; 1998 Jan; 18(1):156-63. PubMed ID: 9412496
[TBL] [Abstract][Full Text] [Related]
9. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiology and biochemical analysis of cyclocreatine uptake and effect in hippocampal slices.
Enrico A; Patrizia G; Luisa P; Alessandro P; Gianluigi L; Carlo G; Maurizio B
J Integr Neurosci; 2013 Jun; 12(2):285-97. PubMed ID: 23869866
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of analgo of phosphocreatine in muscle of chicks fed 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).
Griffiths GR; Walker JB
J Biol Chem; 1976 Apr; 251(7):2049-54. PubMed ID: 1270421
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.
Kurmi K; Hitosugi S; Yu J; Boakye-Agyeman F; Wiese EK; Larson TR; Dai Q; Machida YJ; Lou Z; Wang L; Boughey JC; Kaufmann SH; Goetz MP; Karnitz LM; Hitosugi T
Cell Metab; 2018 Dec; 28(6):833-847.e8. PubMed ID: 30174304
[TBL] [Abstract][Full Text] [Related]
13. Creatine and cyclocreatine attenuate MPTP neurotoxicity.
Matthews RT; Ferrante RJ; Klivenyi P; Yang L; Klein AM; Mueller G; Kaddurah-Daouk R; Beal MF
Exp Neurol; 1999 May; 157(1):142-9. PubMed ID: 10222117
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
15. Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
Okumu DO; Aponte-Collazo LJ; Dewar BJ; Cox NJ; East MP; Tech K; McDonald IM; Tikunov AP; Holmuhamedov E; Macdonald JM; Graves LM
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129507. PubMed ID: 31881245
[TBL] [Abstract][Full Text] [Related]
16. Myocardial protection during ischemia by prior feeding with the creatine analog: cyclocreatine.
Jacobstein MD; Gerken TA; Bhat AM; Carlier PG
J Am Coll Cardiol; 1989 Jul; 14(1):246-51. PubMed ID: 2738267
[TBL] [Abstract][Full Text] [Related]
17. The two sides of creatine in cancer.
Zhang L; Bu P
Trends Cell Biol; 2022 May; 32(5):380-390. PubMed ID: 34895811
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
19. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
20. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
